A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are hoping they will persuade more Americans to get the updated shot.
and German partner BioNTech
kicked things off with news that early data from a Phase 2/3 clinical trial of their omicron BA.4/BA.5-adapted bivalent booster showed positive results in treating individuals aged 18 and older.
The data collected seven days after administering a 30-ug booster dose showed a “substantial increase” in neutralizing antibodies, the companies said in a joint statement.
“While we expect more mature immune response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults,” Pfizer CEO Albert Bourla said in a statement.
“These early data suggest that our bivalent vaccine is anticipated to provide better protection against currently circulating variants than the original vaccine and potentially help to curb future surges in cases this winter.”
The companies expect to provide additional data at 1-month post administration in the coming weeks.
said its combination COVID-19 vaccine and flu shot candidate generated an immune response in a Phase 1/2 clinical trial.
Novavax also said that the safety and tolerability of the combination vaccine was consistent with getting a standalone COVID-19 vaccine or flu shot, and it plans to begin a confirmatory Phase 2 clinical trial this year.
The global tally of COVID cases fell 10% in the week through Oct. 9 from the previous week, the World Health Organization said in its weekly update on the pandemic.
The number of fatalities was stable versus the previous week at about 9,000.
Omicron remained the dominant variant, accounting for 99.9% of cases sequenced in the last 30 days and forwarded to a central database. The BA.5 descendent lineage remains the dominant subvariant, accounting for 76.2% of cases.
U.S. known cases of COVID are continuing to ease and now stand at their lowest level since late April, although the true tally is likely higher given how many people overall are testing at home, where the data are not being collected.
The daily average for new cases stood at 38,828 on Wednesday, according to a New York Times tracker, down 20% from two weeks ago. Cases are rising in just three states and Puerto Rico, namely New Mexico, Kansas and Vermont. They are flat in Wisconsin and Wyoming and down everywhere else.
The daily average for hospitalizations was down 7% at 26,690, while the daily average for deaths is down 2% to 377.
Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began
Other COVID-19 news you should know about:
• The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna and Pfizer/BioNTech. Moderna’s
new shot is now available for children between the ages of 6 and 17 years old, while the BioNTech/Pfizer bivalent booster is now available for children between the ages of 5 and 11 years old.
• Taiwan lifted all its COVID entry restrictions on Thursday, allowing tourists unfettered access to the self-ruled island after over 2 1/2 years of border controls, the Associated Press reported. Hong Kong and Taiwan, together with mainland China, required most visitors to complete a mandatory quarantine period throughout the pandemic, even as most countries reopened their borders to tourists.
The new bivalent vaccine might be the first step in developing annual Covid shots, which could follow a similar process to the one used to update flu vaccines every year. Here’s what that process looks like, and why applying it to Covid could be challenging. Illustration: Ryan Trefes
• Scores on the ACT college admissions test by this year’s high-school graduates hit their lowest point in more than 30 years — the latest evidence of the enormity of learning disruption during the pandemic, the AP reported separately. The class of 2022′s average ACT composite score was 19.8 out of 36, marking the first time since 1991 that the average score was below 20. What’s more, an increasing number of high-school students failed to meet any of the subject-area benchmarks set by the ACT — showing a decline in preparedness for college-level coursework. The test scores were made public in a report Wednesday.
• Police rushed to a highway bridge in Beijing after a column of dark smoke appeared above protest banners condemning Chinese leader Xi Jinping by name—a rare display of defiance in the capital that came as top Communist Party officials arrived to attend a closely watched political gathering, The Wall Street Journal reported. Video footage and photographs of the smoke and two banners—one of which had “Depose the Traitorous Dictator Xi Jinping” scrawled on it in red—circulated widely on Chinese social-media platforms Thursday.
Here’s what the numbers say:
The global tally of confirmed cases of COVID-19 topped 623.3 million on Monday, while the death toll rose above 6.56 million, according to data aggregated by Johns Hopkins University.
The U.S. leads the world with 96.8 million cases and 1,064,072 fatalities.
The Centers for Disease Control and Prevention’s tracker shows that 225.9 million people living in the U.S., equal to 68% of the total population, are fully vaccinated, meaning they have had their primary shots. Just 110.5 million have had a booster, equal to 48.9% of the vaccinated population, and 24.8 million of those who are eligible for a second booster have had one, equal to 37.9% of those who received a first booster.
Some 11.5 million people have had a shot of the new bivalent booster that targets the new omicron subvariants.